F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diagnostic Imaging
Conditions
Diagnostic Imaging
Trial Timeline
Oct 1, 2009 → Oct 1, 2010
NCT ID
NCT01009359About F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102)
F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) is a phase 1 stage product being developed by Bayer for Diagnostic Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT01009359. Target conditions include Diagnostic Imaging.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01009359 | Phase 1 | Completed |
Competing Products
11 competing products in Diagnostic Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) | Johnson & Johnson | Phase 3 | 77 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| BAY86-4367 + BAY86-4367 | Bayer | Phase 1 | 30 |
| Ultravist (Iopromide, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Gadopentetate dimeglumine (Magnevist, BAY86-4882) | Bayer | Pre-clinical | 20 |
| Gadoxetic Acid Disodium (Primovist, BAY86-4873) | Bayer | Pre-clinical | 20 |
| Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance) | Bayer | Phase 3 | 74 |
| Xenetix + Visipaque | Guerbet | Approved | 77 |
| Iobitridol | Guerbet | Approved | 77 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |